Aine Hanly serves as Chief Technology Officer at Vir Biotechnology, where she is responsible for overseeing the Company’s technical operations. Her purview includes product and process development, supply chain, manufacturing, quality, and CMC strategy for multi-modality products addressing the world’s most serious infectious diseases, including COVID-19, hepatitis B virus, influenza A, and human immunodeficiency virus. Dr. Hanly’s career in the biomanufacturing industry, which has spanned roles in the UK, Ireland, and the US, has been dedicated to advancing innovative solutions to accelerate commercialization and the delivery of medicines to patients.
Prior to joining Vir, Dr. Hanly served as the Vice President of Process Development for Amgen, accountable for clinical manufacturing and global supply of clinical trial materials. During her nearly decade-long tenure, she led teams enabling the commercialization of Amgen’s pipeline products as well as providing technical support for ongoing commercial manufacturing operations. Additionally, as site head at Amgen’s Cambridge facility, Dr. Hanly led the site’s transformation and staff growth, and together with the research and development team, greatly increased Amgen’s partnerships and presence within the local Cambridge ecosystem. She also worked for more than ten years at Pfizer (formerly Wyeth), where she held roles of increasing responsibility in analytical R&D, process development, and quality and product supply strategy.
Dr. Hanly received her bachelor’s degree in biological chemistry and a PhD in physical organic chemistry from the University of Ulster, Northern Ireland. She completed her post-doctoral fellowship at Creighton University School of Medicine before joining the collaborative research wing at Yale University and CuraGen Corporation as a lead scientist studying gene isolation and subsequent confirmation using various molecular biology techniques.